Valneva SE (EPA:VLA)
4.024
-0.276 (-6.42%)
At close: Nov 28, 2025
Valneva SE Revenue
Valneva SE had revenue of 48.33M EUR in the quarter ending June 30, 2025, with 26.98% growth. This brings the company's revenue in the last twelve months to 196.33M, up 30.21% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
196.33M
Revenue Growth
+30.21%
P/S Ratio
3.84
Revenue / Employee
252.33K
Employees
713
Market Cap
691.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | 7.74M | 7.35% |
| Dec 31, 2017 | 105.29M | 7.40M | 7.56% |
| Dec 31, 2016 | 97.89M | 14.56M | 17.47% |
| Dec 31, 2015 | 83.33M | 40.91M | 96.41% |
| Dec 31, 2014 | 42.43M | 6.44M | 17.89% |
| Dec 31, 2013 | 35.99M | 326.00K | 0.91% |
| Dec 31, 2012 | 35.67M | 2.78M | 8.46% |
| Dec 31, 2011 | 32.88M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
Valneva SE News
- 4 days ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 4 days ago - Valneva to Further Consolidate its Operations in France - GlobeNewsWire
- 4 days ago - Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study - WSJ
- 4 days ago - Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate - GlobeNewsWire
- 10 days ago - Valneva SE (INRLF) Nine Months 2025 Earnings Call Highlights: Revenue Growth Amid Operational ... - GuruFocus
- 10 days ago - Valneva SE (VALN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Nine Months 2025 Valneva SE Earnings Call Transcript - GuruFocus
- 10 days ago - Valneva SE 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha